Clinical study on Zhuang medicine Fuzheng compound in the treatment of advanced epidermal growth factor receptor sensitive mutant non-small cell lung cancer / 国际中医中药杂志

Objective:To evaluate Zhuang medicine Fuzheng compound combined with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of advanced epidermal growth factor receptor (EGFR) sensitive mutant non-small cell lung cancer (NSCLC).Methods:A total of 120 patients with advanced NSCLC who met the inclusion criteria from June 2019 to May 2020 in Guangxi International Zhuang Medical Hospital were divided into 2 groups according to the random number table method, with 60 in each group. The control group was treated with TKIs, and the observation group was treated with Zhuang medicine Fuzheng compound combined with EGFR-TKIs. TCM syndrome scores were compared, and the quality of life of the patients was assessed by the Quality of Life Scale (QLQ-C30). The serum levels of carcinoembryonic antigen (CEA), squamous cell carcinoma associated antigen (SCC-Ag) and carbohydrate antigen 50 (CA50) were detected by radioimmunoassay, and the levels of CD3 +, CD4 +, and CD8 + were detected by flow cytometry, and the CD4 +/CD8 + ratio was calculated. The adverse reactions during the treatment were observed and recorded. Results:The objective remission rate in the observation group was 66.7% (40/60) and the disease control rate was 81.7% (49/60), while in the control group were 48.3% (29/60) and 63.3% (38/60), respectively.The differences were statistically significant ( χ2 values were 4.13 and 5.06, P values were 0.042 and 0.025, respectively). After treatment, the scores of chest tightness, shortness of breath, blood in sputum, mental fatigue in the observation group were significantly lower than those in the control group ( t values were 8.72, 5.02, 5.47, all Ps<0.001), After treatment, QLQ-C30 score in the observation group was significantly higher than that of the control group ( t=5.21, P<0.01). After treatment, CEA [(31.45±4.56) mU/L vs. (38.98±5.71) mU/L, t=7.98], SCC-Ag [(4.87±0.93) μg/L vs. (7.29±1.25) μg/L, t=12.03], CA50 [(58.27±7.14) U/L vs. (66.48±7.94) U/L, t=5.96] levels were significantly lower than those in the control group ( P<0.01); CD3 +[(52.43±5.01)% vs. (48.56±4.87)%, t=4.29], CD4 + [(54.89±5.03)% vs. (51.09±5.22)%, t=4.06], CD4 +/CD8 + [(1.95±0.28) vs. (1.65±0.27), t=5.97] significantly higher than those in the control group ( P<0.01), CD8 + [(28.12±2.70)% vs. (31.23±2.64)%, t=6.38] significantly lower than that of the control group ( P<0.01). During the treatment period, the incidence of adverse reactions in the observation group was 13.3% (8/60) and that in the control group was 8.3% (5/60), with a statistically significant difference between two groups ( χ 2=0.78, P=0.378). Conclusion:The Zhuang medicine Fuzheng compound combined with EGFR-TKIs can reduce the level of tumor markers in patients with advanced EGFR-sensitive mutant NSCLC, improve patients' TCM syndromes, quality of life, enhance patient immunity, and improve efficacy.

Study on the activity of anti-platelet aggregation of Dendrobium denneanum / 国际中医中药杂志

Objective To study the anti-platelet aggregation activity of Dendrobium denneanum. Methods A total of 21 rats were randomly divided into the extract 1 group, the extract 2 group, the extract 3 group, the extract 4 group, the extract 5 group, the extract 6 group and the positive control group, with 3 in each group. While 9 guinea pigs were randomly divided into the extract 5 group, the extract 6 group and the positive control group, 3 guinea pigs per group. The platelet aggregation was induced by adenosine triphosphate (ADP) in vitro in rats and arachidonic acid (AA) in vitro in guinea pigs. Plate let rich plasma (PRP) was collected. Each group of PRP was added with different concentrations of Dendrobium denneanum extract 1, 2, 3, 4, 5, 6 or aspirin to intervene. The maximal aggregation rate were detected in 5 min, and to calculate the inhibition rate of platelet aggregation and half of each test substance inhibitory concentration (IC50). Asp was detected in 5 min. The above steps were repeated three times. The inhibition rate of platelet aggregation and the IC50 of each subject were calculated. The maximum aggregation rate of the drug delivery group and the blank control group was compared to evaluate the antithrombotic activity of the Dendrobium with two different induction methods. Results Compared with the blank control group, the maximal aggregation rate induced by ADP of the extract 12.399 mmol/L dose group, the extract 28.96 mmol/L dose group, the extract 317.505 mmol/L dose group , the extract 57.836, 3.918 mmol/L dose group, the extract 60.755, 0.377 mmol/L dose group (32.57% ± 0.28% vs. 45.20% ± 2.64%), (16.66% ± 3.67% vs. 39.37% ± 8.05%), (0.00% ± 0.00% vs. 32.52% ± 3.05%), (1.11% ± 1.93%, 7.49% ± 9.47% vs. 43.54% ± 10.68%), (8.66% ± 7.50%, 22.71% ± 8.24% vs. 40.65% ± 6.61%) significantly decreased (P<0.05 or P<0.01). Compared with the blank control group, the maximal aggregation rate induced by AA of the extract 57.836 mmol/L dose group, the extract 60.377 mmol/L dose group (0.00% ± 0.00% vs. 52.97% ± 5.49%), (0.00% ± 0.00% vs. 53.47% ± 6.04%) significantly decreased (P<0.05 or P<0.01). The IC50 of extracts 5 and 6 were 3.143 and 0.100 mmol/L, respectively. Conclusions There were many kinds of ingredients in Dendrobium denneanum which had anti-platelet aggregation activity. Dendrobium denneanum had positive effects on thrombotic diseases.

Inhibitory effects of Hes1 on acute myeloid leukemia cells / 中华血液学杂志

<p><b>OBJECTIVE</b>To elucidate the impact of Hes1 on the proliferation and apoptosis of acute myeloid leukemia (AML) cells.</p><p><b>METHODS</b>The expression levels of Hes1 and p21 in AML patient samples and myeloid leukemia cell lines were analyzed by real-time PCR. Hes1 was up-regulated by retrovirus transfection in AML cell lines and the proliferation capacity were assayed by MTT, cell cycle by Hoechst/PY, apoptosis by AnnexinV.</p><p><b>RESULTS</b>The expression of Hes1 in primary AML cells and HL-60, U937, KG1a cell lines were 0.67 ± 0.24, 0.59 ± 0.43, 0.42 ± 0.03, and 0.32 ± 0.26, respectively, and p21 were 0.54 ± 0.01, 0.44 ± 0.12, 0.36 ± 0.12, and 0.59 ± 0.43, respectively. Hes1 expression levels after transduction in HL-60, U937, KG1a were 4.9 ± 0.2, 5.2 ± 0.4, 5.8 ± 0.5, respectively. Induced activation of Hes1 led to AML cells growth arrest and apoptosis, which was associated with an enhanced p21 expression. Besides, activated Hes1 led to AML cells growth inhibition in vivo.</p><p><b>CONCLUSION</b>Hes1 could mediate growth arrest and apoptosis in AML cells, which may be a novel target for AML.</p>

Importance of data management with statistical analysis set division / 药学学报

Testing of hypothesis was affected by statistical analysis set division which was an important data management work before data base lock-in. Objective division of statistical analysis set under blinding was the guarantee of scientific trial conclusion. All the subjects having accepted at least once trial treatment after randomization should be concluded in safety set. Full analysis set should be close to the intention-to-treat as far as possible. Per protocol set division was the most difficult to control in blinded examination because of more subjectivity than the other two. The objectivity of statistical analysis set division must be guaranteed by the accurate raw data, the comprehensive data check and the scientific discussion, all of which were the strict requirement of data management. Proper division of statistical analysis set objectively and scientifically is an important approach to improve the data management quality.

Prevention and handling of missing data in clinical trials / 药学学报

Missing data is a common but unavoidable issue in clinical trials. It not only lowers the trial power, but brings the bias to the trial results. Therefore, on one hand, the missing data handling methods are employed in data analysis. On the other hand, it is vital to prevent the missing data in the trials. Prevention of missing data should take the first place. From the perspective of data, firstly, some measures should be taken at the stages of protocol design, data collection and data check to enhance the patients' compliance and reduce the unnecessary missing data. Secondly, the causes of confirmed missing data in the trials should be notified and recorded in detail, which are very important to determine the mechanism of missing data and choose the suitable missing data handling methods, e.g., last observation carried forward (LOCF); multiple imputation (MI); mixed-effect model repeated measure (MMRM), etc.

Clinical analysis of myelodysplastic syndrome/acute myeloid leuke-mia secondary to malignant tumors in 11 cases / 中国肿瘤临床

Objective:To investigate the etiology, clinical characteristics, and treatment of myelodysplastic syndrome/acute my-eloid leukemia (t-MDS/AML) secondary to malignant tumors. Methods: We retrospectively analyzed 11 patients with t-MDS/AML and investigated the treatment of primary tumors, clinical manifestations, treatment, and survival of t-MDS/AML patients. Results:A total of 11 patients were exposed to cytotoxic chemotherapeutic agents or radiation therapy for their primary tumors. The median laten-cy was 36 months. Common symptoms were fatigue, dyspnea, bleeding, and infection, all of which were related to deficits in hemato-poiesis. Therapeutic regimen included support therapy, immunomodulatory therapy, and chemotherapy. The median overall survival and disease-free survival periods were 28 months and 19 months, respectively, and the overall survival rate for 3 years was 44.4%. Conclu-sion:t-MDS/AML is a serious complication of chemotherapy or radiotherapy for a malignant or nonmalignant condition. The curative effect is limited, and prognosis is poor. Therefore, we should take t-MDS/AML into consideration when making treatment plans for can-cer patients to evaluate treatment benefits and to avoid treatment-related complications.

In vitro synergistic effect of arsenic trioxide with conventional or new drugs on the proliferation of cutaneous T cell lymphoma cells Hut-78 and Hut-102 / 中国肿瘤临床

Objective:To investigate the in vitro effect of arsenic trioxide (As2O3) alone and in combination with dexamethasone (DXM), etoposide (VP-16), methotrexate (MTX), bortezomib (BTZ), and suberoylanilide hydroxamic acid (SAHA) on the growth of human cutaneous T cell lymphoma (CTCL) cells Hut-78 and Hut-102. Methods:Hut-78 and Hut-102 cells were cultured with different concentrations of As2O3, DXM, VP-16, MTX, BTZ, and SAHA alone and As2O3 in combination with DXM, VP-16, MTX, BTZ, or SAHA for 48 h. The effects of the different samples on Hut-78 and Hut-102 cell proliferation were determined by MTT assay. Analyses using CalcuSyn software were performed to determine whether the combination of As2O3 with DXM, VP-16, MTX, BTZ, or SAHA in-duced synergistic cytoxicity. Results:As2O3, DXM, VP-16, MTX, BTZ, and SAHA alone significantly inhibited the growth of Hut-78 and Hut-102 cells in a dose-dependent manner, with a 50%inhibiting concentration of 5μmol/L, 500μg/mL, 2.5μg/mL, 1μg/mL, 10μmol/L, and 2.5μmol/L individually after 48 h of culture. As2O3 with DXM, VP-16, MTX, BTZ, or SAHA showed remarkable antitu-mor efficacy compared with that of individual applications. Conclusion:As2O3 alone or combined with DXM, VP-16, MTX, BTZ, or SAHA significantly inhibited Hut-78 and Hut-102 cell growth in vitro. This study demonstrated that As2O3 with DXM, VP-16, MTX, BTZ, or SAHA presents synergistic antitumor effects on CTCL cells and may be an optimal regimen in clinical trials of CTCL.

The study about plasma biochemical index among the hypertension in Xining area / 国际检验医学杂志

Objective To study the plasma biochemical indexes among the hypertension in Xining area.Methods According to diagnosis standard of hypertension,104 males who emigrated to Xining area were divided into hypertension group and control group,height,weight,blood routine,renal function,blood lipid of the two groups were measured.Results Among the 104 subjects, 17 cases were hypertensive patients,and other 87 cases were served as control group.The body weight,blood uric acid levels in hy-pertension group were significantly higher than those in the control group(P <0.05),the other indexes had no significant difference between two groups.Conclusion The uric acid may be a risk factor for hypertension people living in plateau area,and the mecha-nism need to be further studied.

The design and construction of medical multimedia teaching resource library / 中华医学教育探索杂志

Building a medical multimedia teaching resource library is beneficial to distance medical education and the efficiency of multimedia resource usage. Its construction depends on not only modern information technology and the network, but also a comprehensive design from the angle of resource integration.

More activity and less toxicity of extracts from solid fermented medicinal plant Tripterygium wilfordii / 中草药

Objective In order to reduce the toxicity and still maintain the bioactivity of the medicinal plant Tripterygium wilfordii(TW),the whole plant biotransfomed method was employed.By observing the pharmacological activities and the toxicity of MeOH extracts from the root of T.wilfordii that were biotransformed by the fungi Aspergillums spp.and Rhizopus spp.,the best biotransformed fungi strain has been selected based on the experimental data.Methods Applying the models of acute and chronic inflammation, the weight of immune organ and cell immunity were used to study the pharmacological activities,and ip injection to observe the acute toxicity.Results The anti-inflammation and immunosuppression have been increased slightly and the toxicity decreased significantly after being biotransformed by Aspergillus spp.(TW1),while the anti-inflammation,immunosuppression,and the toxicity have been declined after being biotransformed by Rhizopus spp.(TW2).Conclusion Although both selected fungi could change the pharmacological activities and toxicity of the T.wilfordii,Aspergillus spp.is better than Rhizopus spp.